Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05831787 · OUTCOME

Patient Reported COVID 19 Related Outcomes on Study

COVID19 OutcomeS in Myeloma and the Impact of VaCcines · Source last updated 2026-05-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
During 6 month study period

What was measured

Patient reported outcomes related to confirmed COVID-19 infection. COVID-19-related outcomes were assessed through a decentralized approach using patient-reported data collected via study questionnaires. Outcomes included participant-reported COVID-19 infection and related clinical events (e.g., hospitalization).

Analysis population: The total enrollment for the study was 201 patients. Although the initial enrollment goal was 200 patients, an additional participant consented before the study was closed to enrollment. However, this participant did not complete any study procedures. Four additional patients either withdrew or did not provide a response for this data variable.

Groups in this outcome

Diagnosis of Multiple Myeloma and Currently Receiving Active Treatment for Any Phase of the Disease

Diagnosis of multiple myeloma must meet the International Myeloma Working Group criteria. Patient Reported Outcomes: Patients will be asked to complete baseline, 30-day, and 6-month clinical and patient reported outcome health surveys.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Diagnosis of Multiple Myeloma and Currently Receiving Active Treatment for Any Phase of the Disease196

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Diagnosis of Multiple Myeloma and Currently Receiving Active Treatment for Any Phase of the Disease0Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        0
denoms
  1. counts
    1. group Id
      OG000
      value
      196
    units
    Participants
description
Patient reported outcomes related to confirmed COVID-19 infection. COVID-19-related outcomes were assessed through a decentralized approach using patient-reported data collected via study questionnaires. Outcomes included participant-reported COVID-19 infection and related clinical events (e.g., hospitalization).
groups
  1. description
    Diagnosis of multiple myeloma must meet the International Myeloma Working Group criteria. Patient Reported Outcomes: Patients will be asked to complete baseline, 30-day, and 6-month clinical and patient reported outcome health surveys.
    id
    OG000
    title
    Diagnosis of Multiple Myeloma and Currently Receiving Active Treatment for Any Phase of the Disease
param Type
COUNT_OF_PARTICIPANTS
population Description
The total enrollment for the study was 201 patients. Although the initial enrollment goal was 200 patients, an additional participant consented before the study was closed to enrollment. However, this participant did not complete any study procedures. Four additional patients either withdrew or did not provide a response for this data variable.
reporting Status
POSTED
time Frame
During 6 month study period
title
Patient Reported COVID 19 Related Outcomes on Study
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice